글로벌 지속성 상피 결손 치료 시장 – 2023-2030

Overview
Global persistent epithelial defect treatment market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The global persistent epithelial defect treatment market has witnessed significant growth and transformations over the years, with various factors influencing its dynamics. The failure of fast re-epithelialization and closure between 10–14 days of a corneal injury, even when using routine supportive therapy, results in persistent epithelial defects (PEDs or PCEDs).
Although they are uncommon, they present a management challenge since they frequently resist supportive care. To prevent potential side effects like infection, corneal scarring, vision loss, melting, and possibly perforation, persistent epithelial abnormalities require immediate and watchful treatment.
Government investments and research, particularly in developing economies, will continue to drive utilization of advanced technology for neurotrophic keratitis and boost the global persistent epithelial defect treatment market.
Market Dynamics: Drivers & Restraints
Growing collaborations and license agreements
Developed economies have been witnessing rapid growth in betterment of their healthcare sectors, driven by high investments, income levels, and infrastructure development. Several countries have experienced substantial demand for persistent epithelial defect treatment owing to the rising research. Various collaborations, acquisitions and license agreement with technological advancements among different countries will be a crucial factor driving the growth of the market.
On July 19, 2023, Santen Pharmaceutical Co., Ltd. had executed asset transfer and license agreements with two American businesses. Santen and Visiox Pharmaceuticals, Inc. have reached an out-licensing agreement regarding the rights to OMLONTI's production, marketing, and sales. In accordance with the terms of the contract, Santen is going to sell and transfer Natacyn (an eyedrop for conjunctivitis, fungal blepharitis, and keratitis), Flarex, ZERVIATE, TobraDex ST, and FRESHKOTE to Harrow Health while granting Harrow Health exclusive rights for the product's production and commercialization in the United States and Canada.
Additionally, on April 28, 2023, the California Institute for Regenerative Medicine (CIRM) granted Combangio, Inc., Kala's entirely owned subsidiary, a $15 million grant to help fund its in progress KPI-012 program to treat cases of persistent corneal epithelial defect (PCED). Kala Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical stage dedicated to the discovery, development, and marketing of innovative treatments for rare and severe diseases of the eye.
Furthermore, the rising utilization of novel medicines and solutions for treatment purposes. Rising epithelial defects and increasing surgical procedures along with research for innovative product development will be a major factor driving the growth of the Persistent Epithelial Defect Treatment market.
Complications associated with the artificial tears or sterile ocular ointments
The conventional medical approach for therapy starts with forceful lubrication using artificial tears without preservatives and sterile eye ointments. They give the epithelium a context in which it can recover its typical structure and function. All concurrent drugs that can obstruct or postpone re-epithelialization must be stopped.
To guard against bacterial and fungal contamination, many commercialized artificial tears include preservatives, most frequently benzalkonium chloride. These preservatives have been shown to sting the eyes as well as if used regularly, can harm the eye's epithelium and induce ocular toxicity.
Segment Analysis
The global persistent epithelial defect treatment market is segmented based on disease type, treatment, end user and region.
Ophthalmic solutions treatment segment accounted for approximately 67% of market share
The use of eye drops made from serum to treat PED is growing in popularity. In addition to lubricating the ocular surface, tears contain high concentrations of growth factors and cytokines that are typically found in natural tears, such as vitamin E, vitamin A, EGF, PDGF, TGF-, FGF, substance P, fibronectin, IGF, or NGF. These factors help epithelial cells proliferate and migrate.
NGF has emerged as the model protein for the group of proteins known as neurotrophins, which are involved in the growth and protection of neurons. Following secretion, the proenzyme, pro-NGF, is latent until it is activated by cleavage, at which point it can connect to cell-surface receptors. Numerous studies have indicated the promise of NGF as a treatment for many ocular surface diseases.
On January 9, 2023, positive topline outcomes from the second phase of the double-masked, randomized, vehicle-controlled clinical study (EXPEDE) assessing two topically administered amounts of NEXAGON (lufepirsen ophthalmic gel) for the management of persistent corneal epithelial defect (PCED), supplementary to chemical and/or therapy, were released by the privately owned biopharmaceutical company in clinical-stage, Amber Ophthalmics, Inc.
Geographical Penetration
North America accounted for around 38% of market share in 2022
Due to the rising need for persistent epithelial defect treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for persistent epithelial defect treatment.
Increasing expenditure on healthcare, advancement of technologies and different types of products for treatment, along with increase in biopharmaceutical or biotechnology business establishment across the region are also contributing to the growth of persistent epithelial defect treatment market share of this region. The market in this area is growing as people become more aware of various novel innovative systems. The aforementioned elements attest to North America's hegemonic position in the world.
North America continues to be a key player in the global persistent epithelial defect treatment market, with United States leading the way. Government initiatives promoting infrastructure development and investment, and a focus on rising advancements have fueled the demand for persistent epithelial defect treatment in the United States have been proactive in executing several initiatives or surgical procedures, stimulating persistent epithelial defect medications demand.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global persistent epithelial defect treatment market. As countries grappled with lockdowns, supply chain disruptions and reduced economic activity, the pharmaceutical sector, with a significant consumer of various treatments, was significantly impacted. The widespread lockdowns and restrictions imposed by the pandemic, which began in early 2020, had an effect on a number of initiatives all around the world.
Major medical and biotechnology industries came to a standstill and shifted their attention towards the management of COVID-19, leading to a slump in demand for persistent epithelial defect treatment. Now several research studies have been initiated and companies have again started trial for their products efficiency. Overall, the impact of the pandemic on the global persistent epithelial defect treatment market is expected to be relatively moderate, with the market continuing to grow steadily due to the ongoing need and research for innovative products, like ophthalmic solutions.
Key Developments
• On April 12, 2023, the U.S. Food and Drug Administration (FDA) has awarded Fast Track designation for KPI-012, human mesenchymal stem cell secretome (MSC-S) therapy by Kala for the management of persistent corneal epithelial defect (PCED), an uncommon and crippling ocular condition. Kala Pharmaceuticals, Inc., a biopharmaceutical company in the clinical stage, committed to the discovery, development, and marketing of novel therapies for rare and serious conditions of the eye.
• On January 3, 2023, the safety and effectiveness of RGN-259 eyedrops in a clinical study in phase 3 in patients having Neurotrophic Keratopathy (NK) are described in a new scientific publication released by RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug manufacturer with a focus on tissue repair, protection, and regeneration. ReGenTree, LLC, a United States-based joint venture between HLB Therapeutics and RegeneRx Biopharmaceuticals, is developing the product candidate. The effectiveness and safety of RGN-259 in accelerating the recovery of persistent epithelial defects among patients having Stage 2 and Stage 3 NK were determined by the study.
• On July 18, 2022, a worldwide ophthalmology contract research company (CRO) and HLB Therapeutics (HLBT), the U.S. joint venture (JV) partner and licensee of RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company specializing in tissue repair, protection, and regeneration, have signed an agreement of intent to execute two phase 3 clinical trials concurrently for patients having neurotrophic keratitis (NK) starting in the U.S. and Europe.
Competitive Landscape
The major global players in the market include Dompé, Santen Pharmaceutical Co., Ltd., Noveome Biotherapeutics, Inc., Recordati Rare Diseases, Kala Pharmaceuticals, Corza Ophthalmology, Amber Ophthalmics, Kiora Pharmaceuticals, Inc., MimeTech Srl and Cordlife.
Why Purchase the Report?
• To visualize the global persistent epithelial defect treatment market segmentation based on disease type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of persistent epithelial defect treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global persistent epithelial defect treatment market report would provide approximately 61 tables, 59 figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies